Healthcare / BiotechnologyHKSE
$2.60
+0.01 (+0.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-297.8M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.3%
↓Gross Margin
50.2%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-828.9%
FCF / Net income
1.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.0M · net income $-209.0M · FCF $-265.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.0M | $32.0M | $69.3M | $18.8M | — |
| Net Income | $-209.0M | $-209.0M | $-237.5M | $-385.0M | $-407.3M |
| EBITDA | $-147.6M | $-147.6M | $-174.4M | $-327.9M | $-369.1M |
| EPS | -0.38 | -0.38 | -0.43 | -0.71 | -0.75 |
| Gross Margin | 50.2% | 50.2% | 74.7% | 76.0% | — |
| Operating Margin | -861.6% | -861.6% | -411.9% | -2409.1% | — |
| Net Margin | -653.6% | -653.6% | -342.6% | -2053.5% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.13 | 0.12 | 0.06 |
| Current Ratio | 4.18 | 4.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-265.0M | $-265.0M | $-297.8M | $-418.9M | $-569.6M |
| Returns | |||||
| ROE | -13.3% | -13.3% | -12.5% | -18.8% | -17.3% |
| Valuation | |||||
| P/B | 0.90 | 0.90 | 0.37 | 0.78 | 0.75 |
| Growth & Yield | |||||
| Revenue Growth | -53.9% | -53.9% | 269.7% | — | — |
| EPS Growth | 11.6% | 11.6% | 39.4% | 5.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.43 → -0.38
Residual
+16.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.